ycoguqi.wordpress.com
Exelixis (NASDAQ: EXEL) also will receive guaranteed research fundinvgof $21 million over three years from the French drugmakert (NYSE: SNY), but over several years could win $1 billion in regulatory and commercial milestone payments. Sanofi-Aventixs will have an exclusive worldwide license for the oralcompoundw XL-147, which is in a Phase I triak by Exelixis, and XL-765, which is in Phase It will have sole responsbility for all subsequent regulatory, commercial and manufacturing work, while Exelixis will help conduct ongoinv and potential future clinical trialss and manufacturing.
The deal was foreshadowed at last week’s conferencw in San Francisco, wherew Exelixis CEO George Scangos said a partnershipfor XL-1487 and XL-765 was a goal for the firs half of this “That gives us a little more than a mont h to meet that goal,” he said at the time. Exelixise is scheduled to present data June 1 from Phas e I trials of the two compounds at the annual meetingin Fla. Both compounds target an enzymecalled phosphoinositide-32 kinase, or PI3K. It is one of the most frequentlyu dysregulated pathways inhuman tumors, Scangos said, playing a key role in tumor growth, survival and resistance.
Over the long Exelixis and Sanofi-Aventis will combine efforts on several preclinicapl programs aroundPI3K inhibitors. Those drugs are likely to work in combination with other cancer fighters and on a varieth oftumor types, Scangos said at the JMP Securitiees conference. “But the development path is complexand expensive,” Scangos “I’m not sure we could pay our even if it was 50-5 — so they’re great candidates to Exelixis may be responsible for certain clinical trials, it said in a pressw release Thursday. The deal is second this month.
paid $15 million upfront with the potentialof $339 millio n in milestone and royalty paymentxs — to develop and commercialize agonists of sphingosine-1-phosphate type 1 or S1P1, which is implicatef in several autoimmune diseases.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment